Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
07:00am, Thursday, 11'th Jul 2024
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma shares encouraging dry eye data
09:10am, Wednesday, 10'th Jul 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The study involved 240 patients and showed that 68% of them had imp
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
07:00am, Wednesday, 10'th Jul 2024
LONDON and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event
08:39am, Tuesday, 09'th Apr 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial of lead asset OK-101 in dry eye disease originally planned for April
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
07:00pm, Monday, 08'th Apr 2024
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms
08:52am, Friday, 22'nd Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various indicators and symptoms associated with Dry Eye Disease (DE
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease
09:23am, Thursday, 21'st Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the anticipated release of comprehensive efficacy data from its Phase 2 trial of OK-101
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
07:00am, Thursday, 21'st Mar 2024
- Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDA
OKYO Pharma to release Phase 2 dry eye disease trial results on Friday
08:55am, Wednesday, 20'th Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of its investigational therapeutic OK-101 in dry eye disease on Friday, March 22, wi
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
07:00am, Wednesday, 20'th Mar 2024
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial
08:47am, Friday, 09'th Feb 2024
OKYO Pharma Ltd (NASDAQ:OKYO) shares moved higher ahead of Friday's opening bell after the biopharmaceutical firm announced that the US Food and Drug Administration (FDA) has cleared its first Investi
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
07:00am, Friday, 09'th Feb 2024
LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
